Subconjunctival Bevacizumab Immediately After Excision of Primary Pterygium: The First Clinical Trial

Purpose: To investigate the effect of subconjunctival bevacizumab immediately after excision of primary pterygium. Methods: Eighty patients (80 eyes) with primary pterygium were included in this double-blind clinical trial. The pterygia were excised by the bare sclera technique. Then, the patients were randomized in 2 equal groups; group A received subconjunctival bevacizumab (1.25 mg/0.1 mL) injected immediately after surgical excision of the pterygium, and placebo was administered in the same way in group B. Patients were followed-up for 9 months after the operation, and the possible complications and recurrence rate were documented. Thirty-three patients (33 eyes) completed the study in each group. Results: The rate of complications was comparable between the 2 groups (57.6% in group A versus 63.6% in group B; P = 0.61). None of these complications was clinically significant, and they resolved spontaneously or by using conservative measures. The recurrence rate was higher in group B compared with group A (57.6% vs. 45.5%); however, this difference was not statistically significant (P = 0.33; odds ratio, 1.63; 95% confidence interval, 0.62–4.31). Conclusions: Subconjunctival injection of bevacizumab immediately after surgical excision of primary pterygium is well-tolerated, but it cannot significantly prevent the recurrence of this condition.

[1]  J. Thariat,et al.  The role of radiotherapy in the treatment of pterygium: a review of the literature including more than 6000 treated lesions. , 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[2]  I. J. van der Meulen,et al.  Long-Term Follow-Up of Pterygium Surgery Using a Conjunctival Autograft and Tissucol , 2011, Cornea.

[3]  L. Vannozzi,et al.  Recurrence Rate Using Fibrin Glue-Assisted Ipsilateral Conjunctival Autograft in Pterygium Surgery: 2-Year Follow-up , 2010, Cornea.

[4]  R. Daneshvar,et al.  Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications. , 2010, American journal of ophthalmology.

[5]  K. Angioi,et al.  L’autogreffe limbo-conjonctivale dans la prise en charge chirurgicale des ptérygions , 2010 .

[6]  K. Angioi,et al.  [Limbal-conjunctival autograft in pterygium surgery]. , 2010, Journal francais d'ophtalmologie.

[7]  Y. Ozkurt,et al.  Treatment of Primary Pterygium , 2009, Optometry and vision science : official publication of the American Academy of Optometry.

[8]  A. Mansour,et al.  Treatment of inflamed pterygia or residual pterygial bed , 2009, British Journal of Ophthalmology.

[9]  F. Grehn,et al.  Antiangiogene Therapie bei Pterygiumrezidiven , 2009, Der Ophthalmologe.

[10]  M. Altaweel,et al.  Bevacizumab (Avastin) for the treatment of ocular disease. , 2009, Survey of ophthalmology.

[11]  C. Teng,et al.  Effect of Subconjunctival Bevacizumab on Primary Pterygium , 2009, Cornea.

[12]  N. Erol,et al.  Long-Term Results of Bare Sclera, Limbal-Conjunctival Autograft and Amniotic Membrane Graft Techniques in Primary Pterygium Excisions , 2009, Ophthalmologica.

[13]  Silvana Artioli Schellini,et al.  Segurança e efetividade no tratamento do pterígio usando infiltração de 5-fluoruracila no intraoperatório , 2009 .

[14]  C. Foster,et al.  Pterygia: Pathogenesis and the Role of Subconjunctival Bevacizumab in Treatment , 2009, Seminars in ophthalmology.

[15]  M. Tai,et al.  Topical Bevacizumab Eyedrops for Limbal-Conjunctival Neovascularization in Impending Recurrent Pterygium , 2009, Cornea.

[16]  A. Alpay,et al.  Comparing techniques for pterygium surgery , 2008, Clinical ophthalmology.

[17]  G. Geerling,et al.  [Antiangiogenic therapy for pterygium recurrence]. , 2009, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[18]  C. Padovani,et al.  [Safety and efficacy of intraoperative 5-fluorouracil infiltration in pterygium treatment]. , 2009, Arquivos brasileiros de oftalmologia.

[19]  I. Bahar,et al.  Subconjunctival Bevacizumab Injection for Corneal Neovascularization in Recurrent Pterygium , 2008, Current eye research.

[20]  R. Bansal,et al.  Human Amniotic Membrane Transplantation With Fibrin Glue in Management of Primary Pterygia: A New Tuck-in Technique , 2008, Cornea.

[21]  C. Bekibele,et al.  Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft , 2008, Eye.

[22]  F. Ziemssen,et al.  Bevacizumab: Off-label use in ophthalmology , 2007, Indian journal of ophthalmology.

[23]  E. Ioachim,et al.  Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1 , 2007, Eye.

[24]  D. Miyazaki,et al.  Prognosis-determinant candidate genes identified by whole genome scanning in eyes with pterygia. , 2007, Investigative ophthalmology & visual science.

[25]  D. Tan,et al.  Current concepts and techniques in pterygium treatment , 2007, Current opinion in ophthalmology.

[26]  P. Chévez-Barrios,et al.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) , 2006, British Journal of Ophthalmology.

[27]  S. Wolf,et al.  Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. , 2006, American journal of ophthalmology.

[28]  I. Scott,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY) , 2006, Retina.

[29]  Toshihiko Inoue,et al.  Postoperative Irradiation for Pterygium , 2006, Strahlentherapie und Onkologie.

[30]  P. Prabhasawat,et al.  Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. , 2006, Ophthalmology.

[31]  A. Solomon,et al.  Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence. , 2005, American journal of ophthalmology.

[32]  Toshihiko Inoue,et al.  Postoperative irradiation for pterygium: retrospective analysis of 1,253 patients from the Osaka University Hospital. , 2006, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[33]  T. Pufe,et al.  Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. , 2005, Ophthalmology.

[34]  F. Raiskup,et al.  Mitomycin C for pterygium: long term evaluation , 2004, British Journal of Ophthalmology.

[35]  C. Bekibele,et al.  5‐fluorouracil vs. beta‐irradiation in the prevention of pterygium recurrence , 2004, International journal of clinical practice.

[36]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[37]  M. Guan,et al.  Decreased Pigment Epithelium-Derived Factor and Increased Vascular Endothelial Growth Factor Levels in Pterygia , 2003, Cornea.

[38]  G. Schultz,et al.  Connective tissue growth factor in pterygium: simultaneous presence with vascular endothelial growth factor – possible contributing factor to conjunctival scarring , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.

[39]  Y. Bar-dayan,et al.  Angiogenesis in pterygium: Morphometric and immunohistochemical study , 2002, Current eye research.

[40]  Jun-Sub Choi,et al.  Expression of Vascular Endothelial Growth Factor and Inducible Nitric Oxide Synthase in Pterygia , 2001, Cornea.

[41]  J. Pikkel,et al.  Halting Pterygium Recurrence by Postoperative 5-Fluorouracil , 2001, Cornea.

[42]  D. Wakefield,et al.  The pathogenesis of pterygia. , 1999, Current opinion in ophthalmology.

[43]  L W Hirst,et al.  Pterygium recurrence rate at the Princess Alexandra Hospital. , 1991, Australian and New Zealand journal of ophthalmology.